Epigenetic blood test separates early breast cancer from healthy samples and flags recurrence risk

Researchers in Israel have developed a blood test that reads epigenetic marks on DNA-protein fragments released by dying cells. It distinguished women with early-stage breast cancer from healthy women with 95% accuracy, and separated patients whose disease returned from those whose did not with 81% accuracy. The wor…